- Home
- KRUS vs RCUS Comparison
KRUS vs RCUS Comparison
Compare KRUS & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRUS
- RCUS
- Stock Information
- Founded
- KRUS 2008
- RCUS 2015
- Country
- KRUS United States
- RCUS United States
- Employees
- KRUS N/A
- RCUS N/A
- Industry
- KRUS Restaurants
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- KRUS Consumer Discretionary
- RCUS Health Care
- Exchange
- KRUS Nasdaq
- RCUS Nasdaq
- Market Cap
- KRUS 1.1B
- RCUS 1.2B
- IPO Year
- KRUS 2019
- RCUS 2018
- Fundamental
- Price
- KRUS $58.87
- RCUS $13.90
- Analyst Decision
- KRUS Buy
- RCUS Buy
- Analyst Count
- KRUS 8
- RCUS 7
- Target Price
- KRUS $96.50
- RCUS $22.00
- AVG Volume (30 Days)
- KRUS 272.9K
- RCUS 937.9K
- Earning Date
- KRUS 11-05-2025
- RCUS 11-05-2025
- Dividend Yield
- KRUS N/A
- RCUS N/A
- EPS Growth
- KRUS N/A
- RCUS N/A
- EPS
- KRUS N/A
- RCUS N/A
- Revenue
- KRUS $269,327,000.00
- RCUS $262,000,000.00
- Revenue This Year
- KRUS $20.51
- RCUS N/A
- Revenue Next Year
- KRUS $20.27
- RCUS N/A
- P/E Ratio
- KRUS N/A
- RCUS N/A
- Revenue Growth
- KRUS 18.76
- RCUS 6.07
- 52 Week Low
- KRUS $40.03
- RCUS $6.50
- 52 Week High
- KRUS $110.66
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- KRUS 21.26
- RCUS 68.53
- Support Level
- KRUS $78.07
- RCUS $12.89
- Resistance Level
- KRUS $78.34
- RCUS $16.12
- Average True Range (ATR)
- KRUS 3.55
- RCUS 0.73
- MACD
- KRUS -1.89
- RCUS 0.07
- Stochastic Oscillator
- KRUS 4.60
- RCUS 44.17
About KRUS Kura Sushi USA Inc.
Kura Sushi USA Inc is a technology-enabled restaurant concept serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. It offers several dishes, including Dashi Olive Salmon, Tomago, Sweet Shrimp, Tuna, Garlic Tuna Steak, and Salmon, among others.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.